Causes, Characteristics and Treatment of Hypercalcemia in the Emergency Room of a German Hospital

June 20, 2024 updated by: Volker Burst, University of Cologne

Retrospective Analysis of Causes, Clinical Presentation and Treatment in Patients With Hypercalcaemia in the Emergency Department of a Tertiary German Hospital

Patients with hypercalcemia were identified in the patient population of a German emergency department during a 11 year time period and studied regarding reproducibility of elevated calcium values, causes of hypercalcemia, symptoms. acute renal injury, mortality and treatment response.

Study Overview

Status

Active, not recruiting

Conditions

Detailed Description

Patients, who presented to the emergency department of a tertiary German hospital with a total calcium of ≥2.65 mmol/l between January 2010 and March 2021, was retrospectively studied. From the electronic patient records we analyzed if the elevated calcium values were reproducible in follow-up measurements, identified the cause of hypercalcemia, listed the symptoms, investigated a correlation between calcium and creatinine values to study acute renal injury directly due to hypercalcemia, calculated the mortality rate stratified by the calcium value on presentation and studied the treatment response regarding lowering calcium values by different treatments.

Study Type

Observational

Enrollment (Actual)

200

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Germany
      • Cologne, Germany, 50937
        • Department II of Internal Medicine,University of Cologne

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients reporting to the Emergency Room of the University Hospital Cologne and recieved a determination of the total calcium level

Description

Inclusion Criteria:

  • Age > 18 years
  • Total calcium ≥ 2.65 mmol/l
  • Female and male

Exclusion Criteria:

  • Age < 18 years
  • Total calcium < 2.65 mmol/

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Retrospective Chart Review
Group includes patient with hypercalcemia ≥2.65 mmol/l, who reported to the emergency room of a tertiary hospital

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Course of total calcium values
Time Frame: 5 days after enrollment
Overview of total calcium values within 5 days
5 days after enrollment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Reproducibility of elevated calcium values
Time Frame: 5 days after enrollment
Determination of cause of hypercalcemia, of symptoms, of treatment response. In dependence of hospital stay, kann be determined later than 5 days after enrollment
5 days after enrollment
Correlation creatinine calcium
Time Frame: 5 days after enrollment
Determination of correlation between calcium and creatinine.
5 days after enrollment
Mortality
Time Frame: 5 days after enrollment
occurence of death within of 5 days after enrollment
5 days after enrollment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University of Cologne

Investigators

  • Principal Investigator: Volker Burst, MD, University Hospital of Cologne

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2010

Primary Completion (Actual)

March 31, 2021

Study Completion (Estimated)

December 31, 2025

Study Registration Dates

First Submitted

June 14, 2024

First Submitted That Met QC Criteria

June 20, 2024

First Posted (Actual)

June 21, 2024

Study Record Updates

Last Update Posted (Actual)

June 21, 2024

Last Update Submitted That Met QC Criteria

June 20, 2024

Last Verified

June 1, 2024

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • V1.0-13.05.2024

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypercalcemia

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Morocco

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe